The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E
Open accessAbstract
Defective binding of apolipoprotein E (apoE) to heparan sulfate proteoglycans (HSPGs) is associated with increased risk of atherosclerosis due to inefficient clearance of lipoprotein remnants by the liver. The interaction of apoE with HSPGs has also been implicated in the pathogenesis of Alzheimer's disease and may play a role in neuronal repair. To identify which residues in the heparin-binding site of apoE and which structural elements of heparan sulfate interact, we used a variety of approaches, including glycosaminoglycan specificity assays, (13)C nuclear magnetic resonance, and heparin affinity chromatography. The formation of the high affinity complex required Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147 from apoE and N- and 6-O-sulfo groups of the glucosamine units from the heparin fragment. As shown by molecular modeling, using a high affinity binding octasaccharide fragment of heparin, these findings are consistent with a binding mode in which five saccharide residues of fully sulfated heparan sulfate lie in a shallow groove of the alpha-helix that contains the HSPG-binding site (helix 4 of the four-helix bundle of the 22-kDa fragment). This groove is lined with residues Arg-136, Ser-139, His-140, Arg-142, Lys-143, Arg-145, Lys-146, and Arg-147. In the model, all of these residues make direct contact with either the 2-O-sulfo groups of the iduronic acid monosaccharides or the N- and 6-O-sulfo groups of the glucosamine sulfate monosaccharides. This model indicates that apoE has an HSPG-binding site highly complementary to heparan sulfate rich in N- and O-sulfo groups such as that found in the liver and the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Presumably, the interaction of apoE with syndecan occurs through electrostatic interactions between positively charged helix 4 domains of apoE and negatively charged sulfate groups in syndecan HSPG (Libeu et al., 2001).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Libeu et al., 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, APOE4 has increased binding affinity (up to two-fold) for heparin and HSPG over APOE3 (refs. 32–35).”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the 22-kDa domain of lipid-bound apoE3[R145C] has 48% reduced HSPG binding capacity compared to apoE3-22kDa [30], [32].”
From Biophysical Analysis of Apolipoprotein E3 Variants Linked with Development of Type III Hyperlipoproteinemia (2011) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the receptor-binding sites (AA136-150) for lipoprotein receptors such as the low-density lipoprotein receptor (LDLR), lipoprotein-related receptor 1 (LRP1), and heparan sulfate proteoglycans (HSPGs) are located in a region conserved between species (Fig. 1a) [11–14].”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Liver heparan sulfate is unusual in that it is more highly sulfated than heparan sulfate in other tissues (54, 56, 57).”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [54]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As hepatocyte HS is notably more enriched in sulfate than HS from endothelium and other tissues (27,33,34), binding of these lipoproteins to liver HS may be preferred to binding to HS in other tissues.”
From Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members (2007) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In general, only 8–12 monosaccharide residues are needed to bind to many proteins, including LPL and apoE (52–55), but the pattern of sulfate groups and uronic acids that mediate TRL binding is unknown.”
From Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice (2009) · cites this paper as [54]
In the citing paper
“apoE is known to bind to heparan sulfate proteoglycan (HSPG) through its N-terminal domain (142–147 amino acid domain) (Libeu et al., 2001).”
From Apolipoprotein E in Synaptic Plasticity and Alzheimer’s Disease: Potential Cellular and Molecular Mechanisms (2014) · cites this paper as Libeu et al., 2001
In the citing paper
“the N-terminal domain site is located between residues 136–147, overlapping with the LDLR binding region (25, 26)”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [26]
In the citing paper
“In addition, the mutation in lysine 146 which disrupts direct ionic interaction between basic residues on apoE and sulfate groups on the GAG chain (26) greatly reduced the favorable free energy for the first binding step to HS and DS (Fig. 4B).”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [26]
In the citing paper
“indicating that the degree of sulfation has a major effect on the electrostatic interaction of GAG with apoE.”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [26]
In the citing paper
“quantitative information on the interaction with various GAG molecules is limited (26, 34).”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [26]
In the citing paper
“However, the large decreases in the association rate and the favorable free energy of binding in the first step observed for HS and DS compared to heparin (Fig. 3) indicate that the contribution of the initial electrostatic interaction to the overall binding is lower for HS and DS than for heparin (26).”
From Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study (2008) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394
MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures
Kraulis, P. J. (1991) · Journal of Applied Crystallography · doi:10.1107/s0021889891004399 · Cited by 14,011
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
[26] Raster3D: Photorealistic molecular graphics
Merritt, E. A., & Bacon, D. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)77028-9 · Cited by 3,749
Williams Textbook of Endocrinology
Melmed, S., & Polonsky, K. S. (2016) · Elsevier eBooks · doi:10.1016/c2013-0-15980-6 · Cited by 3,715
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Williams Textbook of Endocrinology
Stoffer, S. S. (1999) · JAMA · doi:10.1001/jama.281.9.851 · Cited by 1,245
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Self-citationHeparin Structure and Interactions with Basic Fibroblast Growth Factor
Faham, S., Hileman, R. E., Fromm, J. R., Linhardt, R. J., & Rees, D. C. (1996) · Science · doi:10.1126/science.271.5252.1116 · Cited by 798
Self-citationMahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
(1998) · Elsevier eBooks · doi:10.1016/b978-0-12-186060-8.x5000-1 · Cited by 504
Mahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Purification of antithrombin III by affinity chromatography
Miller-Andersson, M., Borg, H., & Andersson, L. (1974) · Thrombosis Research · doi:10.1016/0049-3848(74)90001-2 · Cited by 423
N.m.r. and molecular-modelling studies of the solution conformation of heparin
Mulloy, B., Forster, M. J., Jones, C., & Davies, D. B. (1993) · Biochemical Journal · doi:10.1042/bj2930849 · Cited by 410
Structure of a heparin-linked biologically active dimer of fibroblast growth factor
DiGabriele, A. D., Lax, I., Chen, D. I., Svahn, C. M., Jaye, M., Schlessinger, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31741 · Cited by 357
Holtzman, D. M., Pitas, R. E., Kilbridge, J., Nathan, B., Mahley, R. W., Bu, G., & Schwartz, A. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.21.9480 · Cited by 349
The Molecular and Genetic Basis of Neurological Disease
Trojanowski, J. Q. (1993) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199309000-00013 · Cited by 341
Dong, L. M., Wilson, C., Wardell, M. R., Simmons, T., Mahley, R. W., Weisgraber, K. H., & Agard, D. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31797-0 · Cited by 320
Self-citationBellosta, S., Nathan, B. P., Orth, M., Dong, L.-M., Mahley, R. W., & Pitas, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27063 · Cited by 313
Apolipoprotein E: from atherosclerosis to Alzheimerʼs disease and beyond
Mahley, R. W., & Huang, Y. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00003 · Cited by 308
Domain Structure of Heparan Sulfates from Bovine Organs
Maccarana, M., Sakura, Y., Tawada, A., Yoshida, K., & Lindahl, U. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17804 · Cited by 284
The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments.
Innerarity, T. L., Friedlander, E. J., Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44180-9 · Cited by 276
Self-citationInnerarity, T. L., Pitas, R. E., & Mahley, R. W. (1979) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)50713-4 · Cited by 246
Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3.
Weisgraber, K. H., Rall, S. C., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35898-2 · Cited by 240
Self-citationCell-surface heparan sulfate. Mechanisms of proteoglycan-cell association.
Kjellén, L., Oldberg, Å., & Höök, M. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70479-7 · Cited by 223
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding.
Weisgraber, K. H., Innerarity, T. L., Harder, K. J., Mahley, R. W., Milne, R. W., Marcel, Y. L., & Sparrow, J. T. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44181-0 · Cited by 220
Self-citationLalazar, A., Weisgraber, K. H., Rall, S. C., Giladi, H., Innerarity, T. L., Levanon, A. Z., Boyles, J. K., Amit, B., Gorecki, M., & Mahley, R. W. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68957-4 · Cited by 209
Self-citationLiver heparan sulfate structure. A novel molecular design
Lyon, M., Deakin, J. A., & Gallagher, J. T. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78112-5 · Cited by 202
Diversity does make a difference: fibroblast growth factor-heparin interactions
Faham, S., Linhardt, R. J., & Rees, D. C. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80147-4 · Cited by 155
Self-citation[13] Isolation and characterization of apolipoprotein E
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1986) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(86)28073-8 · Cited by 150
Self-citationAge-dependent Modulation of Heparan Sulfate Structure and Function
Feyzi, E., Saldeen, T. G. P., Larsson, E., Lindahl, U., & Salmivirta, M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13395 · Cited by 144
Ji, Z. S., Fazio, S., & Mahley, R. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36849-7 · Cited by 138
Distribution of sulphate and iduronic acid residues in heparin and heparan sulphate
Höök, M., Lindahl, U., & Iverius, P. (1974) · Biochemical Journal · doi:10.1042/bj1370033 · Cited by 130
Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia
Dong, L., Parkin, S., Trakhanov, S. D., Rupp, B., Simmons, T., Arnold, K. S., Newhouse, Y. M., Innerarity, T. L., & Weisgraber, K. H. (1996) · Nature Structural & Molecular Biology · doi:10.1038/nsb0896-718 · Cited by 129
Self-citationKinnunen, T., Raulo, E., Nolo, R., Maccarana, M., Lindahl, U., & Rauvala, H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.4.2243 · Cited by 127
Orr, G. A. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70041-6 · Cited by 122
Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism
Jon Williams, K., & Fuki, I. V. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199710000-00003 · Cited by 113
Interaction of the N-Terminal Domain of Apolipoprotein E4 with Heparin
Dong, J., Peters-Libeu, C. A., Weisgraber, K. H., Segelke, B. W., Rupp, B., Capila, I., Hernáiz, M. J., LeBrun, L. A., & Linhardt, R. J. (2001) · Biochemistry · doi:10.1021/bi002417n · Cited by 99
Self-citationHorie, Y., Fazio, S., Westerlund, J. R., Weisgraber, K. H., & Rall, S. C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)46040-1 · Cited by 94
Self-citationFunctional Characterization of Apolipoprotein E Isoforms Overexpressed in Escherichia coli
Morrow, J. A., Arnold, K. S., & Weisgraber, K. H. (1999) · Protein Expression and Purification · doi:10.1006/prep.1999.1069 · Cited by 94
Self-citationParthasarathy, N., Goldberg, I. J., Sivaram, P., Mulloy, B., Flory, D. M., & Wagner, W. D. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31802-1 · Cited by 90
Lu, B., Morrow, J. A., & Weisgraber, K. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003508200 · Cited by 89
Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8283 · Cited by 86
Lund‐Katz, S., Ibdah, J. A., Letizia, J. Y., Thomas, M. T., & Phillips, M. C. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68319-x · Cited by 77
Self-citationLindahl, B., Westling, C., Giménez‐Gallego, G., Lindahl, U., & Salmivirta, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30631 · Cited by 70
Reduced Sulfation of Liver Heparan Sulfate in Experimentally Diabetic Rats
Kjellén, L., Bielefeld, D., & Hook, M. (1983) · Diabetes · doi:10.2337/diab.32.4.337 · Cited by 67
The Molecular and Genetic Basis of Neurological Disease
Albin, R. L. (1997) · JAMA · doi:10.1001/jama.1997.03550070091049 · Cited by 65
Cell Surface Proteoglycans Modulate Net Synthesis and Secretion of Macrophage Apolipoprotein E
Lucas, M., & Mazzone, T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.23.13454 · Cited by 63
Effects of Lipid Interaction on the Lysine Microenvironments in Apolipoprotein E
Lund‐Katz, S., Zaiou, M., Wehrli, S. L., Dhanasekaran, P., Baldwin, F., Weisgraber, K. H., & Phillips, M. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005265200 · Cited by 54
Self-citationRiesenfeld, J., Höök, M., & Lindahl, U. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)86121-5 · Cited by 51
Unger, E., Pettersson, I., Eriksson, U. J., Lindahl, U., & Kjellén, L. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)31496-0 · Cited by 43
Mann, W. A., Meyer, N., Weber, W., Meyer, S., Greten, H., & Beisiegel, U. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39885-0 · Cited by 37
Shuvaev, V. V., Laffont, I., & Siest, G. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01285-5 · Cited by 27
Minnich, A., Weisgraber, K. H., Newhouse, Y., Dong, L. M., Fortin, L. J., Tremblay, M., & Davignon, J. (1995) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39754-6 · Cited by 26
Self-citationMärz, W., Hoffmann, M. M., Scharnagl, H., Fisher, E., Chen, M., Nauck, M., Feussner, G., & Wieland, H. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33303-4 · Cited by 21
Heparin specifically inhibits binding of apolipoprotein E to amyloid β-peptide
Shuvaev, V. V., & Siest, G. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00764-3 · Cited by 19
Murata, K., Murata, A., & Yoshida, K. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00049-x · Cited by 14
Conrad, H. E. (1998) · Elsevier eBooks · doi:10.1016/b978-012186060-8/50003-6 · Cited by 11
Cole (2000) · doi:10.1002/1097-0029(20000815)50:4
Flagged first, then by citations
Research works printed but not linked: 1
- Mahley, 1996, Isr. J. Med. Sci., 32, 414
Cited by
Sorted by citations
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2004) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 506
Apolipoprotein E isoforms and lipoprotein metabolism
Phillips, M. C. (2014) · IUBMB Life · doi:10.1002/iub.1314 · Cited by 328
Self-citationTopology of human apolipoprotein E3 uniquely regulates its diverse biological functions
Chen, J., Li, Q., & Wang, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106420108 · Cited by 283
The key role of apolipoprotein E in atherosclerosis
Greenow, K. R., Pearce, N. J., & Ramji, D. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0631-3 · Cited by 243
Stanford, K. I., Bishop, J. R., Foley, E. M., Gonzales, J. C., Niesman, I. R., Witztum, J. L., & Esko, J. D. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38251 · Cited by 226
Metadata
- Authors
- Libeu, C. P., Lund-Katz, S., Phillips, M. C., Wehrli, S., Hernáiz, M. J., Capila, I., Linhardt, R. J., Raffaı̈, R. L., Newhouse, Y. M., Zhou, F., & Weisgraber, K. H.
- Affiliations
- Gladstone Institutes (US)
- Children's Hospital of Philadelphia (US)
- University of Iowa (US)
- Texas A&M University (US)
- Corresponding author
- Weisgraber, Karl H.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-10
- Volume
- 276
- Issue
- 42
- Pages
- 39138-39144
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2106771721
- Cited by
- 113
- References
- 61
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 2 · 2023: 8 · 2022: 4 · 2021: 3 · 2020: 3 · 2019: 5 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 2 · 2014: 5 · 2013: 2 · 2012: 2
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-41633, P01HL041633, R01HL056083, HL-56083, HL 52622, R01HL052622)
- National Institute of General Medical Sciences (GM38060, R01GM038060)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein E, heparan sulfate proteoglycans, heparin-binding site, iduronic acid, glucosamine sulfate, atherosclerosis, Alzheimer's disease, lipoprotein clearance, binding site modeling
- MeSH terms
- Animals, Apolipoproteins E, Arginine, Binding Sites, Brain, Cattle, Chromatography, Affinity, Dose-Response Relationship, Drug, Glucosamine, Heparin, Humans, Hydrogen-Ion Concentration, Kinetics, Liver, Lysine, Models, Molecular, Mutation, Magnetic Resonance Spectroscopy, Polysaccharides, Protein Binding, Serine, Time Factors, Streptavidin, Heparan Sulfate Proteoglycans, Biotinylation, Surface Plasmon Resonance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
